Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lexaria Bioscience Corp WT
(NQ:
LEXXW
)
0.8000
+0.0500 (+6.67%)
Streaming Delayed Price
Updated: 11:59 AM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp WT
< Previous
1
2
3
4
5
6
7
Next >
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
July 27, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 26, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 26, 2022
Via
ACCESSWIRE
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 26, 2022
KELOWNA, BC / ACCESSWIRE / July 26, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Supply Chain
Exposures
Supply Chain
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
July 14, 2022
KELOWNA, BC / ACCESSWIRE / July 14, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study
July 13, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's Human Nicotine Study Nearing Start Date
July 13, 2022
Lexaria is targeting the oral nicotine pouch category, one of the fastest growing segments of the nicotine industry.
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Cannadips is Expanding Internationally, Leveraging Lexaria's DehydraTECH
July 07, 2022
KELOWNA, BC / ACCESSWIRE / July 7, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that...
From
Lexaria Bioscience Corp.
Via
AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Manufacturing, License Agreements with BevNology
June 21, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Signs Manufacturing and License Agreements with BevNology
June 21, 2022
KELOWNA, BC / ACCESSWIRE / June 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Grants License to AnodGen Bioceuticals
June 08, 2022
KELOWNA, BC / ACCESSWIRE / June 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
June 06, 2022
KELOWNA, BC / ACCESSWIRE / June 6, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has...
From
Lexaria Bioscience Corp.
Via
AccessWire
Exposures
Product Safety
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
June 03, 2022
KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce a...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Grants License to Valcon Medical for the European Market
June 02, 2022
KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Cannabis
Exposures
Cannabis
Lexaria Announces 2022 Annual Meeting Results
June 01, 2022
KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals
April 22, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs
April 21, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
April 21, 2022
- 25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date
April 20, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date
April 19, 2022
Via
CannabisNewsWire
Exposures
Product Safety
Lexaria Commences Multi-Week Human Clinical Hypertension Study
April 19, 2022
- HYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefits - This study is designed to enhance Lexaria's probabilities of success with its...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
April 14, 2022
Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
April 13, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Issues Update on Human Nicotine Study
April 13, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
April 12, 2022
Via
CannabisNewsWire
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
April 12, 2022
- Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 /...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
April 11, 2022
KELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
March 16, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
March 15, 2022
- Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; - DehydraTECH-CBD test articles have been delivered to the laboratory ready...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Granted Important New Oral Nicotine Patent
March 08, 2022
Newest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.